Calliditas Therapeutics AB (publ) (CALT)
NASDAQ: CALT · IEX Real-Time Price · USD
19.50
+0.30 (1.57%)
At close: Apr 26, 2024, 4:00 PM
19.34
-0.16 (-0.82%)
After-hours: Apr 26, 2024, 4:00 PM EDT
CALT Revenue
In the year 2023, Calliditas Therapeutics AB (publ) had annual revenue of $119.73M with 55.09% growth.
Revenue (ttm)
$119.73M
Revenue Growth
+55.09%
P/S Ratio
4.37
Revenue / Employee
$623,599
Employees
192
Market Cap
523.32M USD
Revenue Chart
* The company reports in SEK currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 119.73M | 42.53M | 55.09% |
Dec 31, 2022 | 77.20M | 51.72M | 202.95% |
Dec 31, 2021 | 25.48M | 25.38M | 23,808.62% |
Dec 31, 2020 | 106.59K | -19.77M | -99.46% |
Dec 31, 2019 | 19.87M | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Phibro Animal Health | 982.01M |
InnovAge Holding | 720.80M |
Talkspace | 150.05M |
IRadimed | 65.56M |
CureVac | 59.73M |
OmniAb | 34.16M |
Absci | 5.72M |
CALT News
- 3 days ago - Calliditas Therapeutics' 2023 Annual Report Published - PRNewsWire
- 4 days ago - Calliditas Announces Positive NefIgArd Open Label Extension Results - PRNewsWire
- 10 days ago - Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024 - PRNewsWire
- 19 days ago - Calliditas Therapeutics to Attend Conferences in April - PRNewsWire
- 20 days ago - Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires - PRNewsWire
- 20 days ago - Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment - PRNewsWire
- 6 weeks ago - Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon® - PRNewsWire
- 7 weeks ago - Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO® - PRNewsWire